// App-Quantinova.ai

1001 : Adjuvant Capecitabine in Combination with Docetaxel, Epirubicin and Cyclophosphamide in the Treatment of Early Breast Cancer: 10-year Survival Results From the Randomized FinXX Trial

Researchers

Presenter

  • Heikki Joensuu

Principal Investigators

  • Pirkko-Liisa Kellokumpu-Lehtinen

  • Riikka Huovinen

  • Arja Jukkola-Vuorinen

  • Minna Tanner

  • Riitta Kokko

  • Paivi Auvinen

  • Outi Lahdenpera

  • Kenneth Villman

  • Paul Nyandoto

  • Greger Nilsson

  • Marja Murashev

  • Paula Poikonen-Saksela

  • Petri Bono

  • Vesa Kataja

  • Henrik Lindman

Medical Centers

  • Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Helsinki, Finland

  • Department of Oncology, Tampere University Hospital, Tampere, Finland

  • Department of Urology, Turku University Hospital, Turku, Finland

  • Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland

  • Kanta-Hame Central Hospital, Hameenlinna, Finland

  • Department of Oncology, Kuopio University Hospital, Kuopio, Finland

  • Orebro University Hospital, Orebro, Sweden, Orebro, Sweden

  • P-HCH, Lahti, Finland

  • Uppsala University Hospital, Uppsala, Sweden

  • Satakunta Central Hospital, Pori, Finland

  • Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland

  • Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland

  • Jyvaskyla Central Hospital, Jyvaskyla, Finland

Locations

  • Finland

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Capecitabine

  • Epirubicin

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT00114816

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved